搜索
Inhibikase Therapeutics Inc
IKT添加自选
2.100USD
-0.050-2.33%
收盘 09-24 16:00（美东）
329.76M总市值
亏损市盈率 TTM
关于 Inhibikase Therapeutics Inc 公司
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).
Inhibikase Therapeutics Inc 简介
公司代码IKT
公司名称Inhibikase Therapeutics Inc
上市日期Dec 23, 2020
CEOIwicki (Mark T)
员工数量15
证券类型Ordinary Share
年结日Dec 23
公司地址1000 N. West Street, Suite 1200
城市WILMINGTON
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编19801
电话13022953800
网址https://www.inhibikase.com/
公司代码IKT
上市日期Dec 23, 2020
CEOIwicki (Mark T)
Inhibikase Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Christopher H. (Chris) Cabell, M.D.
Dr. Christopher H. (Chris) Cabell, M.D.
President, Head - Research and Development
President, Head - Research and Development
676.56K
--
Dr. Christopher H. (Chris) Cabell, M.D.
Dr. Christopher H. (Chris) Cabell, M.D.
President, Head - Research and Development
President, Head - Research and Development
676.56K
--
Mr. Vincent E. (Vince) Aurentz
Mr. Vincent E. (Vince) Aurentz
Independent Director
Independent Director
510.60K
--
Mr. Vincent E. (Vince) Aurentz
Mr. Vincent E. (Vince) Aurentz
Independent Director
Independent Director
510.60K
--
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Chairman of the Board
Independent Chairman of the Board
403.18K
--
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Chairman of the Board
Independent Chairman of the Board
403.18K
--
Mr. Arvind Kush
Mr. Arvind Kush
Independent Director
Independent Director
145.00K
--
Mr. Arvind Kush
Mr. Arvind Kush
Independent Director
Independent Director
145.00K
--
Mr. Dennis N. Berman
Mr. Dennis N. Berman
Independent Director
Independent Director
21.85K
--
Mr. Dennis N. Berman
Mr. Dennis N. Berman
Independent Director
Independent Director
21.85K
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Christopher H. (Chris) Cabell, M.D.
Dr. Christopher H. (Chris) Cabell, M.D.
President, Head - Research and Development
President, Head - Research and Development
676.56K
--
Dr. Christopher H. (Chris) Cabell, M.D.
Dr. Christopher H. (Chris) Cabell, M.D.
President, Head - Research and Development
President, Head - Research and Development
676.56K
--
Mr. Vincent E. (Vince) Aurentz
Mr. Vincent E. (Vince) Aurentz
Independent Director
Independent Director
510.60K
--
Mr. Vincent E. (Vince) Aurentz
Mr. Vincent E. (Vince) Aurentz
Independent Director
Independent Director
510.60K
--
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Chairman of the Board
Independent Chairman of the Board
403.18K
--
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Chairman of the Board
Independent Chairman of the Board
403.18K
--
常见问题
Inhibikase Therapeutics Inc的前五大股东是谁？
Inhibikase Therapeutics Inc 的前五大股东如下：Dr. Christopher H. (Chris) Cabell, M.D.
有多少机构持有Inhibikase Therapeutics Inc(IKT)的股份？
截至2026Q1，共有152家机构持有Inhibikase Therapeutics Inc的股份，合计持有的股份价值约为103.21M，占公司总股份的78.17%。与2025Q4相比，机构持股有所增加，增幅为43845693.00。